Covered recipient · General Payments record
THOMAS HORN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
General Payments · PY2018–2023
$2,146.22
- Reported across 115 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $389.60 | 16 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $169.77 | 9 |
| ITI, Inc. | $107.60 | 1 |
| Supernus Pharmaceuticals, Inc. | $23.74 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.71 | 1 |
| Alkermes, Inc. | $18.98 | 1 |
| Otsuka America Pharmaceutical, Inc. | $17.65 | 1 |
| Janssen Pharmaceuticals, Inc | $16.03 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $15.12 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.14 | 04/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501261 | CMS |
| ABBVIE INC. | $18.26 | 04/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501263 | CMS |
| ABBVIE INC. | $15.64 | 04/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501265 | CMS |
| ABBVIE INC. | $30.78 | 04/26/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501267 | CMS |
| ABBVIE INC. | $24.55 | 05/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501269 | CMS |
| ABBVIE INC. | $18.09 | 05/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501271 | CMS |
| ABBVIE INC. | $9.70 | 05/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501273 | CMS |
| ABBVIE INC. | $11.10 | 07/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501275 | CMS |
| ABBVIE INC. | $22.51 | 08/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997501277 | CMS |
| Alkermes, Inc. | $18.98 | 05/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1022837065 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $15.12 | 01/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1038216665 | CMS |
| ITI, Inc. | $107.60 | 05/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040562007 | CMS |
| Janssen Pharmaceuticals, Inc | $16.03 | 02/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 988614337 | CMS |
| Otsuka America Pharmaceutical, Inc. | $17.65 | 01/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1014411306 | CMS |
| Supernus Pharmaceuticals, Inc. | $23.74 | 04/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1053262751 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.71 | 05/31/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1055408317 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.